Logo image of ALNOX.PA

NOXXON PHARMA NV (ALNOX.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALNOX - NL0012044762 - Common Stock

0.041 EUR
-0.01 (-18%)
Last: 7/18/2022, 7:00:00 PM
Fundamental Rating

2

ALNOX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. The financial health of ALNOX is average, but there are quite some concerns on its profitability. ALNOX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALNOX has reported negative net income.
ALNOX.PA Yearly Net Income VS EBIT VS OCF VS FCFALNOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -5M -10M

1.2 Ratios

Industry RankSector Rank
ROA -147.9%
ROE N/A
ROIC -219.68%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNOX.PA Yearly ROA, ROE, ROICALNOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 200 -200 400 -400

1.3 Margins

ALNOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALNOX.PA Yearly Profit, Operating, Gross MarginsALNOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

ALNOX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALNOX has been increased compared to 1 year ago.
Compared to 1 year ago, ALNOX has an improved debt to assets ratio.
ALNOX.PA Yearly Shares OutstandingALNOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M
ALNOX.PA Yearly Total Debt VS Total AssetsALNOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

2.2 Solvency

ALNOX has an Altman-Z score of -28.39. This is a bad value and indicates that ALNOX is not financially healthy and even has some risk of bankruptcy.
ALNOX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.39
ROIC/WACC-29.25
WACC7.51%
ALNOX.PA Yearly LT Debt VS Equity VS FCFALNOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.84 indicates that ALNOX should not have too much problems paying its short term obligations.
A Quick Ratio of 1.84 indicates that ALNOX should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
ALNOX.PA Yearly Current Assets VS Current LiabilitesALNOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

ALNOX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.04%, which is quite impressive.
EPS 1Y (TTM)40.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALNOX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.06% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.23%
EPS Next 2Y28.6%
EPS Next 3Y16.4%
EPS Next 5Y10.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNOX.PA Yearly Revenue VS EstimatesALNOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2022 1M 2M 3M 4M 5M
ALNOX.PA Yearly EPS VS EstimatesALNOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALNOX. In the last year negative earnings were reported.
Also next year ALNOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNOX.PA Price Earnings VS Forward Price EarningsALNOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.48
ALNOX.PA Per share dataALNOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

ALNOX's earnings are expected to grow with 16.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.6%
EPS Next 3Y16.4%

More info and screens

0

5. Dividend

5.1 Amount

ALNOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOXXON PHARMA NV

EPA:ALNOX (7/18/2022, 7:00:00 PM)

0.041

-0.01 (-18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.05M
Revenue(TTM)N/A
Net Income(TTM)-14.45M
Analysts84
Price Target7.39 (17924.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB N/A
EV/EBITDA 0.48
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.06
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -147.9%
ROE N/A
ROCE N/A
ROIC -219.68%
ROICexc N/A
ROICexgc -219.88%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -28.39
F-Score3
WACC7.51%
ROIC/WACC-29.25
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.23%
EPS Next Y-19.23%
EPS Next 2Y28.6%
EPS Next 3Y16.4%
EPS Next 5Y10.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

NOXXON PHARMA NV / ALNOX.PA FAQ

Can you provide the ChartMill fundamental rating for NOXXON PHARMA NV?

ChartMill assigns a fundamental rating of 2 / 10 to ALNOX.PA.


What is the valuation status for ALNOX stock?

ChartMill assigns a valuation rating of 3 / 10 to NOXXON PHARMA NV (ALNOX.PA). This can be considered as Overvalued.


How profitable is NOXXON PHARMA NV (ALNOX.PA) stock?

NOXXON PHARMA NV (ALNOX.PA) has a profitability rating of 1 / 10.